195
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Therapeutic strategies for relapsing–remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy

, &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Alberto Gajofatto, Marco Turatti, Salvatore Monaco & Maria Donata Benedetti. (2015) Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug, Healthcare and Patient Safety 7, pages 157-167.
Read now

Articles from other publishers (4)

Suyog Pol, Serena Liang, Ferdinand Schweser, Ravendra Dhanraj, Anna Schubart, Marilena Preda, Michele Sveinsson, Deepa P. Ramasamy, Michael G. Dwyer, Gisbert Weckbecker & Robert Zivadinov. (2021) Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. Experimental Neurology 335, pages 113488.
Crossref
Agustín Pappolla, Francisco Sánchez, Fiorella Caro, Jimena Miguez, Liliana Patrucco, Edgardo Cristiano & Juan Ignacio Rojas. (2020) Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study. Journal of Clinical Neuroscience 74, pages 65-68.
Crossref
Juan I Rojas, Georgina Murphy, Francisco Sanchez, Liliana Patrucco, Maria C Fernandez, Jimena Miguez, Jorge Funes, Angel Golimstok & Edgardo Cristiano. (2018) Thalamus volume change and cognitive impairment in early relapsing–remitting multiple sclerosis patients. The Neuroradiology Journal 31:4, pages 350-355.
Crossref
Sheena L. Dupuy, Shahamat Tauhid, Shelley Hurwitz, Renxin Chu, Fawad Yousuf & Rohit Bakshi. (2016) The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurology and Therapy 5:2, pages 215-229.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.